Avatar-incentive healthcare therapy

Information

  • Patent Grant
  • 11673041
  • Patent Number
    11,673,041
  • Date Filed
    Friday, July 9, 2021
    2 years ago
  • Date Issued
    Tuesday, June 13, 2023
    11 months ago
Abstract
An avatar-incentive healthcare therapy system has a physiological monitor for generating a physiological parameter indicative of physical health. An academic test for generating a test score is indicative of mental acuity. The avatar has outward characteristics and game play capabilities proportional to the physiological health and the mental acuity so as to incentivize improved physical health and academic performance.
Description
BACKGROUND OF THE INVENTION

Medical device manufacturers are continually increasing the processing capabilities of patient monitors, specifically of patient monitors that process signals based on attenuation of light by patient tissue. In general, such patient monitoring systems include one or more optical sensors that irradiate tissue of a patient and one or more photodetectors that detect the radiation after attenuation thereof by the tissue. The sensor communicates the detected signal to a patient monitor, where the monitor often removes noise and preprocesses the signal. Advanced signal processors then perform time domain and/or frequency domain processing to determine measurements of blood constituents and other physiological parameters of the patient.


Manufacturers have advanced basic pulse oximeters that determine measurements for blood oxygen saturation (“SpO2”), pulse rate (“PR”) and pethysmographic information, to read-through-motion oximeters, to co-oximeters that determine measurements of many constituents of circulating blood. For example, Masimo Corporation of Irvine Calif. (“Masimo”) manufactures pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO2, PR, perfusion index (“PI”) and others. Masimo sensors include any of LNOP®, LNCS®, Sofrouch™ and Blue™ adhesive or reusable sensors. Masimo oximetry monitors include any of Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.


Many innovations improving the measurement of blood constituents are described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo and are incorporated by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,088,607; 5,782,757 and 5,638,818, assigned to Masimo and hereby incorporated in their entirety by reference herein.


Masimo also manufactures more advanced co-oximeters including Masimo Rainbow® SET, which provides measurements in addition to SpO2, such as total hemoglobin (SpHb™), oxygen content (SpCO™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Masimo's advanced blood parameter monitors include Masimo Radical-7™, Rad87™, and Rad57™ monitors as well as Pronto and Pronto-7 spot check monitors.


Innovations relating to these more advanced blood parameter measurement systems are described in at least U.S. Pat. Nos. 7,647,083; 7,729,733; U.S. Pat. Pub. Nos. 2006/0211925; and 2006/0238358, assigned to Cercacor Laboratories of Irvine, Calif. (“Cercacor”) and hereby incorporated in their entirety by reference herein.


Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.


Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation (“Masimo”) of Irvine, Calif. and are incorporated in their entirety by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated in their entirety by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO2, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.


Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled Multiple Wavelength Sensor Equalization; U.S. Pat. No. 7,729,733, filed Mar. 1, 2006, titled Configurable Physiological Measurement System; U.S. Pat. Pub. No. 2006/0211925, filed Mar. 1, 2006, titled Physiological Parameter Confidence Measure and U.S. Pat. Pub. No. 2006/0238358, filed Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Monitor, all assigned to Cercacor Laboratories, Inc., Irvine, Calif. (Cercacor) and all incorporated in their entirety by reference herein. An advanced parameter measurement system that includes acoustic monitoring is described in U.S. Pat. Pub. No. 2010/027 4099, filed Dec. 21, 2009, titled Acoustic Sensor Assembly, assigned to Masimo and incorporated in its entirety by reference herein.


Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SpO2, such as total hemoglobin (SpHb™), oxygen content (SpOC™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical7™, Rad87™ and Rad57™ monitors, all available from Masimo. Advanced parameter measurement systems may also include acoustic monitoring such as acoustic respiration rate (RRa™) using a Rainbow Acoustic Sensor™ and Rad87™ monitor, available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.


SUMMARY OF THE INVENTION

An avatar-incentive healthcare therapy system has a physiological monitor for generating a physiological parameter indicative of physical health. An academic test for generating a test score is indicative of mental acuity. The avatar has outward characteristics and game play capabilities proportional to the physiological health and the mental acuity so as to incentivize improved physical health and academic performance.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-B are perspective views of a physiological monitor and corresponding monitor screens incorporating avatar-incentives for healthcare therapy;



FIGS. 2A-C are avatar illustrations incorporating healthcare therapy incentives;



FIG. 3 are perspective views of physiological monitors and interfaced devices for incentivizing healthcare therapy;



FIG. 4 is a block diagram of physiological monitor communications for incentivizing healthcare therapy; and



FIG. 5 is a block diagram of a cloud-based physiological monitoring system for avatar-incentive healthcare therapy.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT


FIGS. 1A-B illustrate a physiological monitor 100 and corresponding monitor screens 101, 102 incorporating avatar-incentives for encouraging physical and mental fitness. As shown in FIG. 1A, the physiological monitor 100 has a hand held processing device 110, a touch screen display 120, a noninvasive optical sensor 130, a sensor cable 140 electrically and mechanically interconnecting the processing device 110 and the sensor 130, a monitor-integrated test strip reader 170 that accepts test strips 175, one or more input keys 150 and an integrated camera 160 among other features. An optical sensor is described in detail with respect to U.S. patent Ser. No. 13/646,659 titled Noninvasive Blood Analysis System, filed Oct. 5, 2012, assigned to Cercacor and incorporated in its entirety by reference herein. A blood glucose monitor is described in detail with respect to U.S. patent Ser. No. 13/308,461 titled Handheld Processing Device Including Medical Applications for Minimally and Noninvasive Glucose Measurements, filed Nov. 30, 2011, assigned to Cercacor and incorporated in its entirety by reference herein. A blood glucose monitor and sensor are described in U.S. Ser. No. 13/473,477 titled Personal Health Device, filed May 16, 2012, assigned to Cercacor and incorporated in its entirety by reference herein.


As shown in FIG. 1B, in an embodiment, the touch screen display 120 has a physiological monitor display mode 101 and an incentive game play mode 102. In a physiological monitor display mode 101, the monitor displays measured physiological parameters. In an incentive game play mode 102, the monitor constructs a video player avatar 180 having physical and mental strengths 190 based upon incentivizing criteria described below. In an embodiment, the avatar is inserted into physiological monitor-based video games according to its strengths 190 or exported externally to video games running on standalone video game systems or from the cloud, as described with respect to FIGS. 3-5, below.


Also shown in FIG. 1B, in an incentive game play mode 102, the touch screen display 120 presents one or more video games advantageously incorporating a player avatar 180 that becomes stronger and/or smarter in proportion to the physical and/or mental capabilities of the player as an incentive for patient recovery. In an avatar communications mode, the player avatar and its corresponding physical and mental capabilities, are communicated to an external video game system, as described with respect to FIGS. 3-5, below.


In an embodiment, an avatar summary screen 122 is presented in the game play mode 102 illustrating the player's selected avatar 180 and indicators 190 of the avatar's accumulated physical strength and mental prowess. With respect to physical strength, the physiological monitor 100 is in wireless or wired communications with, for example, exercise equipment so as to incentivize patients recovering from, say, accidents or surgery to track physical exercise and healing progress. With respect to mental prowess, the physiological monitor 100 is in communications with mental skill test results, where the mental skills are either presented by the physiological monitor 100 itself in a mental challenge mode or input to the monitor 100 from external indicators of mental achievements, such as student report cards and standardized test results, to name a few.


In other embodiments, the physiological monitor 100 measures, records and tracks a person's physiological measurements such as resting heart rate, cholesterol, blood pressure among other physiological parameters. The person's avatar becomes physically stronger according to a health index based upon these parameters. Likewise, if a person passes certain quizzes or has a report card with straight A's, that person's avatar gets stronger and smarter for games simulating physical competition, such as racing, sports and combat. Advantageously, the physiological monitor 100 helps patients recovering from a stroke, provides a sports training tool for athletes and functions as a student teaching device, as a few examples.



FIGS. 2A-C illustrate avatars incorporating healthcare therapy incentives. As shown in FIG. 2A, a physiological monitor 110 (FIG. 1A) allows a patient or other user to construct an avatar 201. The avatar's clothing or other external characteristics may overtly display the avatar's physical or mental strength 190 (FIG. 1B) as earned by the patient via improved physiological wellness or mental fitness tests measured by the monitor 110 (FIG. 1A) or provided externally, as described below. In an embodiment, the avatar has clothing 210 that reflects earned physical/mental accomplishments/improvements. In an exemplar embodiment, the avatar's belt color indicates earned physical strength and the avatar's tunic or dress color indicates earned mental strength. For example, a black belt and a bright colored tunic indicates an avatar with high physical and mental strength as the result of high physical and mental test scores and other real-world physical and mental accomplishments. As shown in FIG. 2B, earned avatar physical and mental strength are rewarded through video gaming, such as avatar combat, races and other player contests. As shown in FIG. 2C, avatar rewards may also be displayed on emails, Internet posts and other electronic communications.



FIG. 3 illustrate physiological monitors and interfaced devices for incentivizing healthcare therapy. The video game may be incorporated within one physiological monitor 301 for single player games or incorporated within linked physiological monitors 301, 302 for multiple-player games, as described with respect to FIG. 4, below. Alternatively, a monitor 301 may be interfaced with an external video game system 320 that resides locally or in the cloud, such as an online gaming center 540 (FIG. 5). Physiological data for constructing an avatar's physical strength may be derived by a physiological monitor 301, such as described with respect to FIG. 1, above, game play on an external video player 320, data from wearable activity devices such as fitness bracelets 310, data directly downloaded from a memory device such as a USB key 340 or from physiological data, game play, test scores, report cards 510-540 (FIG. 5) accessed via the cloud 10, as described with respect to FIG. 5, below. Similarly, mental prowess may be assessed by mental ability tests provided by physiological monitor 301, such as described with respect to FIG. 1, above, or from mental prowess data gathered via the cloud or other external sources, such as school grades and standardized test scores, as described with respect to FIG. 5, above. Video game play on a monitor 301 may also be enhanced by interfaced game play devices, such as a joystick 440.



FIG. 4 illustrates physiological monitor communications for incentivizing healthcare therapy. A cloud-based monitor communications system 400 has a cloud server 10 in communications with various physiological monitors 100. In this manner, monitor users 20 may freely network with each other whether located in various hospitals/clinics 410, at home 420, on the street 430 or any location remote from the cloud server 10. Data is transmitted from monitors 100 to the cloud server 10 via wired (e.g. LAN) or wireless (e.g. Wi-Fi) local networks to wide area media, such as Internet cable, telecommunications (e.g. 3G) networks or cellular networks 440. These wide area media, in turn, are in communications with the cloud server 10, which calculates physiological parameters or simply provides patient-to-patient communications including conversations or interactive gaming through their avatars, as described above.



FIG. 5 illustrates a cloud-based physiological monitoring system for avatar-incentive healthcare therapy. A healthcare monitor 560, such as described with respect to FIG. 1 (100), above, incorporating earned avatar incentives, also described above, may be in communications with a physiological data processing center 510, testing centers 520, schools 530 and online gaming centers 540. Physiological data for determining avatar physical strength may be determined from the physiological data processing center 510 and received by the monitor 560. Likewise, data for determining avatar mental acuity may be determined from standardized testing centers 520, e.g. from standard tests such as PSAT, SAT, GMAT, GRE etc. Avatar mental acuity may also be determined from various schools via authorized access to a particular student's grades 530. Further, earned avatar incentives can be exported to and used within games provided by online gaming centers 540. Avatar-incentive healthcare therapy has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications.

Claims
  • 1. A method of generating a computer avatar of a person in a gaming software, the method comprising: receiving a measurement from a physiological monitor;determining a physiological wellness of the person based on the received measurement;determining a mental acuity score based on one or more received test results;assigning one or more characteristics to a computer avatar that reflects the physiological wellness and the mental acuity score;utilizing the computer avatar in the gaming software; andchanging the one or more characteristics of the computer avatar according to a subsequent measurement from the physiological monitor indicating a change in health or fitness of the person.
  • 2. The method according to claim 1, wherein the physiological monitor comprises a wearable fitness monitor.
  • 3. The method according to claim 1, wherein the one or more characteristic comprises clothing.
  • 4. The method according to claim 1, wherein the gaming software is an online gaming software.
  • 5. The method according to claim 1, wherein the one or more characteristics comprises a combat skill of the computer avatar.
  • 6. The method according to claim 1, wherein the one or more characteristics comprises a racing skill of the computer avatar.
  • 7. The method of claim 1, wherein the measurement is responsive to tracking an exercise activity of the person.
  • 8. The method according to claim 1, wherein the physiological monitor comprises a wearable fitness monitor.
  • 9. The method according to claim 1, wherein the one or more characteristics comprises a combat skill of the computer avatar.
  • 10. The method according to claim 1, wherein the one or more characteristics comprises a racing skill of the computer avatar.
  • 11. A system for generating a computer avatar of a person in a gaming software, the system comprising one or more hardware processors configured to: receive a measurement from a physiological monitor;determine a physiological wellness of the person based on the received measurement;determine a mental acuity score based on one or more received test results;assign one or more characteristics to a computer avatar that reflects the physiological wellness and the mental acuity score;utilize the computer avatar in the gaming software; andchange the one or more characteristics of the computer avatar based on the determined one or more characteristics according to a subsequent measurement from the physiological monitor.
INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

The present application claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 61/916,136 filed Dec. 13, 2013, titled Avatar Incentive Video Game, hereby incorporated in its entirety by reference herein.

US Referenced Citations (532)
Number Name Date Kind
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
5436499 Namavar et al. Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5561275 Savage et al. Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5671914 Kalkhoran et al. Sep 1997 A
5726440 Kalkhoran et al. Mar 1998 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5747806 Khalil et al. May 1998 A
5750994 Schlager May 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5890929 Mills et al. Apr 1999 A
5919134 Diab Jul 1999 A
5987343 Kinast Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6010937 Karam et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6040578 Malin et al. Mar 2000 A
6066204 Haven May 2000 A
6115673 Malin et al. Sep 2000 A
6124597 Shehada et al. Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6144868 Parker Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6232609 Snyder et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6255708 Sudharsanan et al. Jul 2001 B1
6280381 Malin et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6411373 Garside et al. Jun 2002 B1
6415167 Blank et al. Jul 2002 B1
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6487429 Hockersmith et al. Nov 2002 B2
6505059 Kollias et al. Jan 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6534012 Hazen et al. Mar 2003 B1
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6587196 Stippick et al. Jul 2003 B1
6587199 Luu Jul 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6635559 Greenwald et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6640117 Makarewicz et al. Oct 2003 B2
6658276 Kiani et al. Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6697656 Al-Ali Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
RE38492 Diab et al. Apr 2004 E
6738652 Mattu et al. May 2004 B2
6760607 Al-Ali Jul 2004 B2
6788965 Ruchti et al. Sep 2004 B2
6816241 Grubisic Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6876931 Lorenz et al. Apr 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6934570 Kiani et al. Aug 2005 B2
6943348 Coffin IV Sep 2005 B1
6956649 Acosta et al. Oct 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6985764 Mason et al. Jan 2006 B2
6990364 Ruchti et al. Jan 2006 B2
6998247 Monfre et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7027849 Al-Ali Apr 2006 B2
D526719 Richie, Jr. et al. Aug 2006 S
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
D529616 Deros et al. Oct 2006 S
7133710 Acosta et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7225006 Al-Ali et al. May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali et al. Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7356365 Schurman Apr 2008 B2
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7377794 Al-Ali et al. May 2008 B2
7395158 Monfre et al. Jul 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7500950 Al-Ali et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7514725 Wojtczuk et al. Apr 2009 B2
7519406 Blank et al. Apr 2009 B2
D592507 Wachman et al. May 2009 S
7530942 Diab May 2009 B1
7593230 Abul-Haj et al. Sep 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7606608 Blank et al. Oct 2009 B2
7620674 Ruchti et al. Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7629039 Eckerbom et al. Dec 2009 B2
7640140 Ruchti et al. Dec 2009 B2
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
D614305 Al-Ali et al. Apr 2010 S
7697966 Monfre et al. Apr 2010 B2
7698105 Ruchti et al. Apr 2010 B2
RE41317 Parker May 2010 E
RE41333 Blank et al. May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
RE41912 Parker Nov 2010 E
7880626 Al-Ali et al. Feb 2011 B2
7909772 Popov et al. Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7941199 Kiani May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7976472 Kiani Jul 2011 B2
7990382 Kiani Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany et al. Sep 2011 E
8028701 Al-Ali et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8182443 Kiani May 2012 B1
8190223 Al-Ali et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8229532 Davis Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8255026 Al-Ali Aug 2012 B1
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8280473 Al-Ali Oct 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 MacNeish, III et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8388353 Kiani et al. Mar 2013 B2
8401602 Kiani Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457707 Kiani Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8630691 Lamego et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8666468 Al-Ali Mar 2014 B1
8670811 O'Reilly Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8688183 Bruinsma et al. Apr 2014 B2
8690799 Telfort et al. Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8755535 Telfort et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8840549 Al-Ali et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8897847 Al-Ali Nov 2014 B2
8911377 Al-Ali Dec 2014 B2
8989831 Al-Ali et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9022930 Sachanandani et al. May 2015 B2
9066666 Kiani Jun 2015 B2
9066680 Al-Ali et al. Jun 2015 B1
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9131881 Diab et al. Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9153112 Kiani et al. Oct 2015 B1
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9245668 Vo et al. Jan 2016 B1
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
D755392 Hwang et al. May 2016 S
9326712 Kiani May 2016 B1
9392945 Al-Ali et al. Jul 2016 B2
9408542 Kinast et al. Aug 2016 B1
9436645 Al-Ali et al. Sep 2016 B2
9445759 Lamego et al. Sep 2016 B1
9474474 Lamego et al. Oct 2016 B2
9480435 Olsen Nov 2016 B2
9510779 Poeze et al. Dec 2016 B2
9517024 Kiani et al. Dec 2016 B2
9532722 Lamego et al. Jan 2017 B2
9560996 Kiani Feb 2017 B2
9579039 Jansen et al. Feb 2017 B2
9622692 Lamego et al. Apr 2017 B2
D788312 Al-Ali et al. May 2017 S
9649054 Lamego et al. May 2017 B2
9697928 Al-Ali et al. Jul 2017 B2
9717458 Lamego et al. Aug 2017 B2
9724016 Al-Ali et al. Aug 2017 B1
9724024 Al-Ali Aug 2017 B2
9724025 Kiani et al. Aug 2017 B1
9749232 Sampath et al. Aug 2017 B2
9750442 Olsen Sep 2017 B2
9750461 Telfort Sep 2017 B1
9775545 Al-Ali et al. Oct 2017 B2
9778079 Al-Ali et al. Oct 2017 B1
9782077 Lamego et al. Oct 2017 B2
9787568 Lamego et al. Oct 2017 B2
9808188 Perea et al. Nov 2017 B1
9839379 Al-Ali et al. Dec 2017 B2
9839381 Weber et al. Dec 2017 B1
9847749 Kiani et al. Dec 2017 B2
9848800 Lee et al. Dec 2017 B1
9861298 Eckerbom et al. Jan 2018 B2
9861305 Weber et al. Jan 2018 B1
9877650 Muhsin et al. Jan 2018 B2
9891079 Dalvi Feb 2018 B2
9924897 Abdul-Hafiz Mar 2018 B1
9936917 Poeze et al. Apr 2018 B2
9955937 Telfort May 2018 B2
9965946 Al-Ali et al. May 2018 B2
D820865 Muhsin et al. Jun 2018 S
9986952 Dalvi et al. Jun 2018 B2
D822215 Al-Ali et al. Jul 2018 S
D822216 Barker et al. Jul 2018 S
10010276 Al-Ali et al. Jul 2018 B2
10086138 Novak, Jr. Oct 2018 B1
10111591 Dyell et al. Oct 2018 B2
D833624 DeJong et al. Nov 2018 S
10123729 Dyell et al. Nov 2018 B2
D835282 Barker et al. Dec 2018 S
D835283 Barker et al. Dec 2018 S
D835284 Barker et al. Dec 2018 S
D835285 Barker et al. Dec 2018 S
10149616 Al-Ali et al. Dec 2018 B2
10154815 Al-Ali et al. Dec 2018 B2
10159412 Lamego et al. Dec 2018 B2
10188348 Al-Ali et al. Jan 2019 B2
RE47218 Al-Ali Feb 2019 E
RE47244 Kiani et al. Feb 2019 E
RE47249 Kiani et al. Feb 2019 E
10205291 Scruggs et al. Feb 2019 B2
10226187 Al-Ali et al. Mar 2019 B2
10231657 Al-Ali et al. Mar 2019 B2
10231670 Blank et al. Mar 2019 B2
RE47353 Kiani et al. Apr 2019 E
10279247 Kiani May 2019 B2
10292664 Al-Ali May 2019 B2
10299720 Brown et al. May 2019 B2
10327337 Schmidt et al. Jun 2019 B2
10327713 Barker et al. Jun 2019 B2
10332630 Al-Ali Jun 2019 B2
10383520 Wojtczuk et al. Aug 2019 B2
10383527 Al-Ali Aug 2019 B2
10388120 Muhsin et al. Aug 2019 B2
D864120 Forrest et al. Oct 2019 S
10441181 Telfort et al. Oct 2019 B1
10441196 Eckerbom et al. Oct 2019 B2
10448844 Al-Ali et al. Oct 2019 B2
10448871 Al-Ali et al. Oct 2019 B2
10456038 Lamego et al. Oct 2019 B2
10463340 Telfort et al. Nov 2019 B2
10471159 Lapotko et al. Nov 2019 B1
10505311 Al-Ali et al. Dec 2019 B2
10524738 Olsen Jan 2020 B2
10532174 Al-Ali Jan 2020 B2
10537285 Shreim et al. Jan 2020 B2
10542903 Al-Ali et al. Jan 2020 B2
10555678 Dalvi et al. Feb 2020 B2
10568553 O'Neil et al. Feb 2020 B2
RE47882 Al-Ali Mar 2020 E
10608817 Haider et al. Mar 2020 B2
D880477 Forrest et al. Apr 2020 S
10617302 Al-Ali et al. Apr 2020 B2
10617335 Al-Ali et al. Apr 2020 B2
10637181 Al-Ali et al. Apr 2020 B2
D887548 Abdul-Hafiz et al. Jun 2020 S
D887549 Abdul-Hafiz et al. Jun 2020 S
10667764 Ahmed et al. Jun 2020 B2
D890708 Forrest et al. Jul 2020 S
10721785 Al-Ali Jul 2020 B2
10736518 Al-Ali et al. Aug 2020 B2
10750984 Pauley et al. Aug 2020 B2
D897098 Al-Ali Sep 2020 S
10779098 Iswanto et al. Sep 2020 B2
10827961 Iyengar et al. Nov 2020 B1
10828007 Telfort et al. Nov 2020 B1
10832818 Muhsin et al. Nov 2020 B2
10849554 Shreim et al. Dec 2020 B2
10856750 Indorf et al. Dec 2020 B2
D906970 Forrest et al. Jan 2021 S
10918281 Al-Ali et al. Feb 2021 B2
10932705 Muhsin et al. Mar 2021 B2
10932729 Kiani et al. Mar 2021 B2
10939878 Kiani et al. Mar 2021 B2
D916135 Indorf et al. Apr 2021 S
D917550 Indorf et al. Apr 2021 S
D917564 Indorf et al. Apr 2021 S
D917704 Al-Ali et al. Apr 2021 S
10987066 Chandran et al. Apr 2021 B2
10991135 Al-Ali et al. Apr 2021 B2
D919094 Al-Ali et al. May 2021 S
D919100 Al-Ali et al. May 2021 S
11006867 Al-Ali May 2021 B2
D921202 Al-Ali et al. Jun 2021 S
11024064 Muhsin et al. Jun 2021 B2
11026604 Chen et al. Jun 2021 B2
D925597 Chandran et al. Jul 2021 S
11058942 Kiani Jul 2021 B2
D927699 Al-Ali et al. Aug 2021 S
11076777 Lee et al. Aug 2021 B2
11114188 Poeze et al. Sep 2021 B2
11147518 Al-Ali et al. Oct 2021 B1
20010034477 Mansfield et al. Oct 2001 A1
20010039483 Brand et al. Nov 2001 A1
20020010401 Bushmakin et al. Jan 2002 A1
20020058864 Mansfield et al. May 2002 A1
20020133080 Apruzzese et al. Sep 2002 A1
20030013975 Kiani Jan 2003 A1
20030018243 Gerhardt et al. Jan 2003 A1
20030144582 Cohen et al. Jul 2003 A1
20030156288 Barnum et al. Aug 2003 A1
20030212312 Coffin, IV et al. Nov 2003 A1
20040002634 Nihtila Jan 2004 A1
20040106163 Workman, Jr. et al. Jun 2004 A1
20050055276 Kiani et al. Mar 2005 A1
20050234317 Kiani Oct 2005 A1
20060073719 Kiani Apr 2006 A1
20060189871 Al-Ali et al. Aug 2006 A1
20070073116 Kiani et al. Mar 2007 A1
20070180140 Welch et al. Aug 2007 A1
20070244377 Cozad et al. Oct 2007 A1
20080064965 Jay et al. Mar 2008 A1
20080094228 Welch et al. Apr 2008 A1
20080221418 Al-Ali et al. Sep 2008 A1
20090036759 Ault et al. Feb 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090095926 MacNeish, III Apr 2009 A1
20090247984 Lamego et al. Oct 2009 A1
20090309891 Karkanias Dec 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100099964 O'Reilly et al. Apr 2010 A1
20100234718 Sampath et al. Sep 2010 A1
20100270257 Wachman et al. Oct 2010 A1
20110028806 Merritt et al. Feb 2011 A1
20110028809 Goodman Feb 2011 A1
20110040197 Welch et al. Feb 2011 A1
20110082711 Poeze et al. Apr 2011 A1
20110086712 Cargill Apr 2011 A1
20110087081 Kiani et al. Apr 2011 A1
20110118561 Tari et al. May 2011 A1
20110137297 Kiani et al. Jun 2011 A1
20110172498 Olsen et al. Jul 2011 A1
20110230733 Al-Ali Sep 2011 A1
20120123231 O'Reilly May 2012 A1
20120165629 Merritt et al. Jun 2012 A1
20120189990 Bavelier et al. Jul 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120226117 Lamego et al. Sep 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130046206 Preminger Feb 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130196297 Anwar Aug 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130345921 Al-Ali et al. Dec 2013 A1
20140004492 O'Reilly et al. Jan 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140180160 Brown et al. Jun 2014 A1
20140187973 Brown et al. Jul 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140316217 Purdon et al. Oct 2014 A1
20140316218 Purdon et al. Oct 2014 A1
20140323897 Brown et al. Oct 2014 A1
20140323898 Purdon et al. Oct 2014 A1
20140323899 Silberstein et al. Oct 2014 A1
20150005600 Blank et al. Jan 2015 A1
20150011907 Purdon et al. Jan 2015 A1
20150073241 Lamego Mar 2015 A1
20150080754 Purdon et al. Mar 2015 A1
20150099950 Al-Ali et al. Apr 2015 A1
20160196388 Lamego Jul 2016 A1
20160283665 Sampath et al. Sep 2016 A1
20160367173 Dalvi et al. Dec 2016 A1
20170024748 Haider Jan 2017 A1
20170173632 Al-Ali Jun 2017 A1
20170251974 Shreim et al. Sep 2017 A1
20170311891 Kiani et al. Nov 2017 A1
20180242926 Muhsin et al. Aug 2018 A1
20180247353 Al-Ali et al. Aug 2018 A1
20180247712 Muhsin et al. Aug 2018 A1
20180256087 Al-Ali et al. Sep 2018 A1
20180310823 Al-Ali et al. Nov 2018 A1
20190117070 Muhsin et al. Apr 2019 A1
20190239787 Pauley et al. Aug 2019 A1
20190320906 Olsen Oct 2019 A1
20190374713 Kiani et al. Dec 2019 A1
20200060869 Telfort et al. Feb 2020 A1
20200111552 Ahmed Apr 2020 A1
20200113435 Muhsin Apr 2020 A1
20200113488 Al-Ali et al. Apr 2020 A1
20200113496 Scruggs et al. Apr 2020 A1
20200113497 Triman et al. Apr 2020 A1
20200113520 Abdul-Hafiz et al. Apr 2020 A1
20200138288 Al-Ali et al. May 2020 A1
20200138368 Kiani et al. May 2020 A1
20200163597 Dalvi et al. May 2020 A1
20200196877 Vo et al. Jun 2020 A1
20200253474 Muhsin et al. Aug 2020 A1
20200253544 Belur Nagaraj et al. Aug 2020 A1
20200275841 Telfort et al. Sep 2020 A1
20200288983 Telfort et al. Sep 2020 A1
20200321793 Al-Ali et al. Oct 2020 A1
20200329983 Al-Ali et al. Oct 2020 A1
20200329984 Al-Ali et al. Oct 2020 A1
20200329993 Al-Ali et al. Oct 2020 A1
20200330037 Al-Ali et al. Oct 2020 A1
20210022628 Telfort et al. Jan 2021 A1
20210104173 Pauley et al. Apr 2021 A1
20210113121 Diab et al. Apr 2021 A1
20210117525 Kiani et al. Apr 2021 A1
20210118581 Kiani et al. Apr 2021 A1
20210121582 Krishnamani et al. Apr 2021 A1
20210161465 Barker et al. Jun 2021 A1
20210236729 Kiani et al. Aug 2021 A1
20210256267 Ranasinghe et al. Aug 2021 A1
20210256835 Ranasinghe et al. Aug 2021 A1
20210275101 Vo et al. Sep 2021 A1
20210290060 Ahmed Sep 2021 A1
20210290072 Forrest Sep 2021 A1
20210290080 Ahmed Sep 2021 A1
20210290120 Al-Ali Sep 2021 A1
20210290177 Novak, Jr. Sep 2021 A1
20210290184 Ahmed Sep 2021 A1
20210296008 Novak, Jr. Sep 2021 A1
Foreign Referenced Citations (1)
Number Date Country
10-0570826 Apr 2006 KR
Related Publications (1)
Number Date Country
20220032173 A1 Feb 2022 US
Provisional Applications (1)
Number Date Country
61916136 Dec 2013 US
Continuations (3)
Number Date Country
Parent 17118323 Dec 2020 US
Child 17372229 US
Parent 16402903 May 2019 US
Child 17118323 US
Parent 14571286 Dec 2014 US
Child 16402903 US